-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] On February 10, the overall performance of the traditional Chinese medicine sector was still bright
.
In terms of individual stocks, as of 13:09, Taiji Group rose by 4.
7%, Jianmin Group, Qianjin Pharmaceutical, Kangenbei and many other stocks rose by more than 3%.
In addition, Yiling Pharmaceutical, Kangyuan Pharmaceutical, Kunming Pharmaceutical Group and Jichuan Pharmaceutical rose by more than 2%, Tongrentang, Lingrui Pharmaceutical, Guangyuyuan, Xintian Pharmaceutical, Guizhou Sanli, Tasly China Resources Sanjiu and others rose slightly
.
Among them, Taiji Group rose by 4.
7%, the current price is 20.
05 yuan, the turnover is 584 million, and the turnover rate is 5.
21%
.
At 11:29 on February 9, the stock hit the daily limit, and it has reached the daily limit 6 times in the past year
.
For the reasons for the change of the stock, the analysis believes that there are three points: First, the company is mainly engaged in the production and sales of Chinese and Western patent medicines
.
The company's main products are Huoxiangzhengqi Oral Liquid, Cefizoxime Sodium for Injection (Yibao Shiling), and Lofencodeine Sustained-Release Tablets (Siweipu),
etc.
Second, the company takes advantage of the existing Taiji Island of Changshou Lake in Chongqing, Wuling Mountain National Forest Park, and part of the land in Tunchang, Hainan to lay out the health care industry and build a four-season health care base
.
Third, the company holds a 15.
65% stake in Chengdu Traditional Chinese Medicine Da Yinhai Eye Hospital Co.
, Ltd.
, and is the second largest shareholder of Yinhai Eye Hospital
.
In addition to Taiji Group, Jianmin Group, Qianjin Pharmaceutical, Kangenbei and many other stocks all rose more than 3%
.
Among them, Jianmin Group is mainly due to the recent release of the performance forecast.
The company's net profit attributable to shareholders of listed companies in 2021 is expected to be about 318 million yuan to 333 million yuan, a year-on-year increase compared with about 148 million yuan in the same period last year.
115% to 125%
.
Qianjin Pharmaceutical is a traditional Chinese medicine stock.
Some analysts believe that it is mainly due to the reform of state-owned enterprises in Hunan, and the concept of Internet celebrity is a hot stock.
.
On February 10, Kangenbei announced that it would transfer 5.
7% of the shares of Guangzhou Magpie Pharmaceuticals, and Tianjin Magpie Pharmaceuticals took over
.
On the whole, there are many factors behind the regaining popularity of Chinese medicine stocks
.
On the news, according to newly released data from the Ministry of Industry and Information Technology, China's traditional Chinese medicine manufacturing industry has a revenue of 619.
6 billion yuan, of which the Chinese patent medicine manufacturing industry has a revenue of 441.
4 billion yuan, and the Chinese medicine decoction piece processing industry has a revenue of 178.
2 billion yuan
.
Chinese patent medicine is widely used in clinical practice
.
Debon Securities believes that in the short and medium term, the traditional Chinese medicine sector will continue to receive market attention, and stocks with low valuations and excellent performance are expected to continue to rise, throughout the spring market in the first quarter, and are expected to achieve a more lasting business cycle
.
At the same time, the positive results of traditional Chinese medicine stocks are also an important reason for the stock price to rebound
.
For example, the above-mentioned Taiji Group is due to the recent announcement of pre-increase in performance
.
Relevant statistics show that as of now, 34 of the 71 traditional Chinese medicine stocks have released 2021 performance forecasts or flash reports, of which 25 are pre-happy, including Dong'e Ejiao, Zhendong Pharmaceutical, Kangenbei, Teyi Pharmaceutical, etc.
, accounting for more than 70%
.
In addition, favorable policies for the traditional Chinese medicine industry are also frequently introduced.
For example, the "Implementation Opinions on Supporting the Inheritance, Innovation and Development of Traditional Chinese Medicine" issued by the State Food and Drug Administration at the end of 2021 clearly includes qualified Chinese herbal decoction pieces, proprietary Chinese medicines, and traditional Chinese medicine preparations in medical institutions.
Medical insurance; on January 30, nine departments including the Ministry of Industry and Information Technology jointly issued the "14th Five-Year Plan for the Development of the Pharmaceutical Industry", which clearly encouraged the development of new Chinese medicines
.
In this regard, CITIC Construction Investment pointed out that since 2021, the implementation of policies at the national level to support the traditional Chinese medicine industry has accelerated significantly
.
The follow-up Chinese medicine market will develop in depth, and relevant companies on the Chinese medicine consumer goods track are worthy of attention
.
.
In terms of individual stocks, as of 13:09, Taiji Group rose by 4.
7%, Jianmin Group, Qianjin Pharmaceutical, Kangenbei and many other stocks rose by more than 3%.
In addition, Yiling Pharmaceutical, Kangyuan Pharmaceutical, Kunming Pharmaceutical Group and Jichuan Pharmaceutical rose by more than 2%, Tongrentang, Lingrui Pharmaceutical, Guangyuyuan, Xintian Pharmaceutical, Guizhou Sanli, Tasly China Resources Sanjiu and others rose slightly
.
Among them, Taiji Group rose by 4.
7%, the current price is 20.
05 yuan, the turnover is 584 million, and the turnover rate is 5.
21%
.
At 11:29 on February 9, the stock hit the daily limit, and it has reached the daily limit 6 times in the past year
.
For the reasons for the change of the stock, the analysis believes that there are three points: First, the company is mainly engaged in the production and sales of Chinese and Western patent medicines
.
The company's main products are Huoxiangzhengqi Oral Liquid, Cefizoxime Sodium for Injection (Yibao Shiling), and Lofencodeine Sustained-Release Tablets (Siweipu),
etc.
Second, the company takes advantage of the existing Taiji Island of Changshou Lake in Chongqing, Wuling Mountain National Forest Park, and part of the land in Tunchang, Hainan to lay out the health care industry and build a four-season health care base
.
Third, the company holds a 15.
65% stake in Chengdu Traditional Chinese Medicine Da Yinhai Eye Hospital Co.
, Ltd.
, and is the second largest shareholder of Yinhai Eye Hospital
.
In addition to Taiji Group, Jianmin Group, Qianjin Pharmaceutical, Kangenbei and many other stocks all rose more than 3%
.
Among them, Jianmin Group is mainly due to the recent release of the performance forecast.
The company's net profit attributable to shareholders of listed companies in 2021 is expected to be about 318 million yuan to 333 million yuan, a year-on-year increase compared with about 148 million yuan in the same period last year.
115% to 125%
.
Qianjin Pharmaceutical is a traditional Chinese medicine stock.
Some analysts believe that it is mainly due to the reform of state-owned enterprises in Hunan, and the concept of Internet celebrity is a hot stock.
.
On February 10, Kangenbei announced that it would transfer 5.
7% of the shares of Guangzhou Magpie Pharmaceuticals, and Tianjin Magpie Pharmaceuticals took over
.
On the whole, there are many factors behind the regaining popularity of Chinese medicine stocks
.
On the news, according to newly released data from the Ministry of Industry and Information Technology, China's traditional Chinese medicine manufacturing industry has a revenue of 619.
6 billion yuan, of which the Chinese patent medicine manufacturing industry has a revenue of 441.
4 billion yuan, and the Chinese medicine decoction piece processing industry has a revenue of 178.
2 billion yuan
.
Chinese patent medicine is widely used in clinical practice
.
Debon Securities believes that in the short and medium term, the traditional Chinese medicine sector will continue to receive market attention, and stocks with low valuations and excellent performance are expected to continue to rise, throughout the spring market in the first quarter, and are expected to achieve a more lasting business cycle
.
At the same time, the positive results of traditional Chinese medicine stocks are also an important reason for the stock price to rebound
.
For example, the above-mentioned Taiji Group is due to the recent announcement of pre-increase in performance
.
Relevant statistics show that as of now, 34 of the 71 traditional Chinese medicine stocks have released 2021 performance forecasts or flash reports, of which 25 are pre-happy, including Dong'e Ejiao, Zhendong Pharmaceutical, Kangenbei, Teyi Pharmaceutical, etc.
, accounting for more than 70%
.
In addition, favorable policies for the traditional Chinese medicine industry are also frequently introduced.
For example, the "Implementation Opinions on Supporting the Inheritance, Innovation and Development of Traditional Chinese Medicine" issued by the State Food and Drug Administration at the end of 2021 clearly includes qualified Chinese herbal decoction pieces, proprietary Chinese medicines, and traditional Chinese medicine preparations in medical institutions.
Medical insurance; on January 30, nine departments including the Ministry of Industry and Information Technology jointly issued the "14th Five-Year Plan for the Development of the Pharmaceutical Industry", which clearly encouraged the development of new Chinese medicines
.
In this regard, CITIC Construction Investment pointed out that since 2021, the implementation of policies at the national level to support the traditional Chinese medicine industry has accelerated significantly
.
The follow-up Chinese medicine market will develop in depth, and relevant companies on the Chinese medicine consumer goods track are worthy of attention
.
